Phosphoinositide 3-kinase δ (PI3Kδ) in respiratory disease

被引:18
|
作者
Stokes, Clare A. [1 ]
Condliffe, Alison M. [1 ]
机构
[1] Univ Sheffield, Sch Med Dent & Hlth, Dept Infect Immun & Cardiovasc Dis, Sheffield, S Yorkshire, England
基金
英国医学研究理事会;
关键词
OBSTRUCTIVE PULMONARY-DISEASE; BRONCHIAL EPITHELIAL-CELLS; RELATIVE CORTICOSTEROID INSENSITIVITY; ALLERGIC AIRWAY INFLAMMATION; CLASS-SWITCH RECOMBINATION; MURINE ASTHMA MODEL; HUMAN IMMUNODEFICIENCY; LUNG-DISEASE; T-CELLS; B-CELL;
D O I
10.1042/BST20170467
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Defining features of chronic airway diseases include abnormal and persistent inflammatory processes, impaired airway epithelial integrity and function, and increased susceptibility to recurrent respiratory infections. Phosphoinositide 3-kinases (PI3K) are lipid kinases, which contribute to multiple physiological and pathological processes within the airway, with abnormal PI3K signalling contributing to the pathogenesis of several respiratory diseases. Consequently, the potential benefit of targeting PI3K isoforms has received considerable attention, being viewed as a viable therapeutic option in inflammatory and infectious lung disorders. The class I PI3K isoform, PI3K delta (Phosphoinositide 3-kinases delta) is of particular interest given its multiple roles in modulating innate and adaptive immune cell functions, airway inflammation and corticosteroid sensitivity. In this mini-review, we explore the role of PI3Kd in airway inflammation and infection, focusing on oxidative stress, ER stress, histone deacetylase 2 and neutrophil function. We also describe the importance of PI3Kd in adaptive immune cell function, as highlighted by the recently described Activated PI3K Delta Syndrome, and draw attention to some of the potential clinical applications and benefits of targeting this molecule.
引用
收藏
页码:361 / 369
页数:9
相关论文
共 50 条
  • [31] Targeting phosphoinositide 3-kinase γ (PI3Kγ) in the treatment of cutaneous leishmaniasis caused by L. mexicana
    Cummings, Hannah Elizabeth
    Barbi, J.
    Keiser, T.
    Zorko, N.
    Lu, B.
    Gerard, C.
    Ruckle, T.
    Seveau, S.
    Rommel, C.
    Whitacre, C.
    Satoskar, A.
    FASEB JOURNAL, 2008, 22
  • [32] Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models
    Spoerke, Jill M.
    O'Brien, Carol
    Huw, Ling
    Koeppen, Hartmut
    Fridlyand, Jane
    Brachmann, Rainer K.
    Haverty, Peter M.
    Pandita, Ajay
    Mohan, Sankar
    Sampath, Deepak
    Friedman, Lori S.
    Ross, Leanne
    Hampton, Garret M.
    Amler, Lukas C.
    Shames, David S.
    Lackner, Mark R.
    CLINICAL CANCER RESEARCH, 2012, 18 (24) : 6771 - 6783
  • [33] Discovery of a novel phosphoinositide 3-kinase gamma (PI3Kγ) inhibitor against hematologic malignancies and theoretical studies on its PI3Kγ-specific binding mechanisms
    Zhu, Jingyu
    Ke, Ke
    Xu, Lei
    Jin, Jian
    RSC ADVANCES, 2019, 9 (35) : 20207 - 20215
  • [34] Phosphatidylinositol 3-kinase (PI3K) inhibitors as anticancer drugs
    Verheijen, Jeroen C.
    Zask, Arie
    DRUGS OF THE FUTURE, 2007, 32 (06) : 537 - 547
  • [35] Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor
    Nylander, S.
    Kull, B.
    Bjorkman, J. A.
    Ulvinge, J. C.
    Oakes, N.
    Emanuelsson, B. M.
    Andersson, M.
    Skarby, T.
    Inghardt, T.
    Fjellstrom, O.
    Gustafsson, D.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2012, 10 (10) : 2127 - 2136
  • [36] Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
    Akinleye, Akintunde
    Avvaru, Parthu
    Furqan, Muhammad
    Song, Yongping
    Liu, Delong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6
  • [37] Regulation of Synoviocyte Migration by phosphoinositide 3 Kinase (PI3K) Delta
    Bartok, Beatrix
    Hammaker, Deepa
    Rommel, Christian
    Firestein, Gary S.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S13 - S14
  • [38] Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
    Akintunde Akinleye
    Parthu Avvaru
    Muhammad Furqan
    Yongping Song
    Delong Liu
    Journal of Hematology & Oncology, 6
  • [39] Multiple stimulants target different phosphoinositide 3-kinase (PI3K) classes in breast cancer cell lines
    Ehrmantrout, Kimberly K.
    Thompson, James E.
    Branch, Angie M.
    CANCER RESEARCH, 2011, 71
  • [40] Differential inhibition of Gβγ-stimulated class IB phosphoinositide 3-kinase γ (PI3Kγ) variants by a monoclonal antibody
    Shymanets, A.
    Prajwal
    Vadas, O.
    Czupalla, C.
    Lopiccolo, J.
    Brenowitz, M.
    Ghigo, A.
    Hirsch, E.
    Krause, E.
    Wetzker, R.
    Williams, R.
    Harteneck, C.
    Nuernberg, B.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2015, 388 : S11 - S12